Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Chlorobutanol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.91 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorobutanol SCHEMBL7670584 | 1.00 | THRB (0.91) | THRBTSHRLMNAALDH1A1 | |
| Chlorobutanol SCHEMBL11215994 | 1.00 | THRB (0.91) | THRBTSHRLMNAALDH1A1 | |
| Chlorobutanol SCHEMBL1043683 | 1.00 | — | — | |
| Chlorobutanol SCHEMBL1040 | 0.95 | — | — | |
| Chlorobutanol SCHEMBL5719643 | 0.95 | THRB (1.00) | THRBTSHRLMNAALDH1A1 | |
| Chlorobutanol SCHEMBL27945422 | 0.91 | — | — | |
| Chlorobutanol SCHEMBL27496467 | 0.91 | — | — | |
| Chlorobutanol SCHEMBL9242282 | 0.91 | — | — | |
| Chlorobutanol SCHEMBL3099727 | 0.87 | THRB (0.83) | THRBTSHRLMNA | |
| Chlorobutanol SCHEMBL28216046 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 400 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025222268-A1 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING ATROPHIC VAGINITIS | JASTLABS CORPORATION (CA) | 2025-10-30 | — | — | WO | claimed |
| WO-2025222280-A1 | STABLE TOPICAL COMPOSITIONS FOR TREATING ATROPHIC VAGINITIS | JASTLABS CORPORATION (CA) | 2025-10-30 | — | — | WO | claimed |
| US-12295921-B2 | Epinephrine spray formulations | Bryn Pharma, LLC (US) | 2025-05-13 | — | — | US | claimed |
| WO-2025090061-A1 | ULTRASONIC INDICATOR DEVICE AND METHOD FOR MONITORING ULTRASONICATION | JP LABORATORIES, INC. (US) | 2025-05-01 | — | — | WO | claimed |
| US-12245995-B2 | Epinephrine spray formulations | Bryn Pharma, LLC (US) | 2025-03-11 | — | — | US | claimed |
| US-12150921-B2 | Epinephrine spray formulations | Bryn Pharma, LLC (US) | 2024-11-26 | — | — | US | claimed |
| EP-4338804-A2 | EPINEPHRINE SPRAY FORMULATIONS | Bryn Pharma, LLC (US) | 2024-03-20 | — | — | EP | claimed |
| US-20230364036-A1 | EPINEPHRINE SPRAY FORMULATIONS | Bryn Pharma, LLC | 2023-11-16 | — | — | US | claimed |
| US-11723884-B2 | Epinephrine spray formulations | Bryn Pharma, LLC (US) | 2023-08-15 | — | — | US | claimed |
| US-20210361594-A1 | EPINEPHRINE SPRAY FORMULATIONS | Bryn Pharma, LLC | 2021-11-25 | — | — | US | claimed |
| US-20160243259-A1 | POLYNUCLEOTIDE COMPOSITIONS CONTAINING AMINO ACIDS | ARES CAPITAL CORPORATION, AS AGENT | 2016-08-25 | — | — | US | claimed |
| EP-3043826-A1 | POLYNUCLEOTIDE COMPOSITIONS CONTAINING AMINO ACIDS | Moderna Therapeutics, Inc. (US) | 2016-07-20 | — | — | EP | claimed |
| WO-2015038892-A1 | POLYNUCLEOTIDE COMPOSITIONS CONTAINING AMINO ACIDS | MODERNA THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | WO | claimed |
| EP-1981988-A2 | ANTISEPTIC COMPOSITIONS AND METHODS OF USING SAME | Do-Coop Technologies Ltd (IL) | 2008-10-22 | — | — | EP | claimed |
| WO-2007077562-A2 | ANTISEPTIC COMPOSITIONS AND METHODS OF USING SAME | DO-COOP TECHNOLOGIES LTD. (IL) | 2007-07-12 | — | — | WO | claimed |
| EP-1363603-B1 | METHOD FOR MAKING WATER SOLUBLE A POORLY WATER-SOLUBLE ANTISEPTIC | CLL PHARMA (FR) | 2005-06-01 | — | — | EP | claimed |
| US-20040137053-A1 | Method for making water soluble a poorly water soluble antiseptic | CCL PHARMA (FR) | 2004-07-15 | — | — | US | claimed |
| EP-1363603-A1 | METHOD FOR MAKING WATER SOLUBLE A POORLY WATER-SOLUBLE ANTISEPTIC | CLL Pharma (FR) | 2003-11-26 | — | — | EP | claimed |
| WO-2002069931-A1 | METHOD FOR MAKING WATER SOLUBLE A POORLY WATER-SOLUBLE ANTISEPTIC | CLL PHARMA (FR) | 2002-09-12 | — | — | WO | claimed |
| US-4888168-A | AQUEOUS MIXTURE WITH GEL OR GEL-FORMER | AMERICAN CYANAMID COMPANY (US) | 1989-12-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12245995-B2 | Epinephrine spray formulations | ADRB2, ADRA2A, ADRA2C | THRB 1514/4885TSHR 1932/4885LMNA 3983/4885 |
| US-12150921-B2 | Epinephrine spray formulations | ADRB2, ADRA2A, ADRA2C | THRB 1514/4885TSHR 1932/4885LMNA 3983/4885 |
| US-20210361594-A1 | EPINEPHRINE SPRAY FORMULATIONS | ADRB2, ADRA2A, ADRA2C | THRB 1514/4885TSHR 1932/4885LMNA 3983/4885 |
| US-12295921-B2 | Epinephrine spray formulations | ADRB2, ADRA2A, ADRA2C | THRB 1514/4885TSHR 1932/4885LMNA 3983/4885 |
| US-20230364036-A1 | EPINEPHRINE SPRAY FORMULATIONS | ADRB2, ADRA2A, ADRA2C | THRB 1514/4885TSHR 1932/4885LMNA 3983/4885 |
| US-11723884-B2 | Epinephrine spray formulations | ADRB2, EPX, ADRB1 | THRB 3745/4885TSHR 3977/4885LMNA 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.